These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 9816399)
1. Current role of immunotherapy in multiple myeloma. Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399 [TBL] [Abstract][Full Text] [Related]
2. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma. Gorschlüter M; Ziske C; Glasmacher A; Schmidt-Wolf IG Clin Cancer Res; 2001 Aug; 7(8):2195-204. PubMed ID: 11489792 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in multiple myeloma--possibility or probability? Harrison SJ; Cook G Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684 [TBL] [Abstract][Full Text] [Related]
4. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in multiple myeloma: current strategies and future prospects. Yi Q Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804 [TBL] [Abstract][Full Text] [Related]
6. [The role of biotherapy in multiple myeloma]. Petrucci MT; Tafuri A; Mandelli F Recenti Prog Med; 2000 Oct; 91(10):488-93. PubMed ID: 11072735 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of multiple myeloma--present status and perspectives]. Robak T Acta Haematol Pol; 1996; 27(1):5-14. PubMed ID: 8629444 [TBL] [Abstract][Full Text] [Related]
8. New approaches to management of multiple myeloma. Hájek R; Vásová I; Adam Z; Mayer J Acta Med Austriaca; 1996; 23(3):91-8. PubMed ID: 8798282 [TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218 [TBL] [Abstract][Full Text] [Related]
17. Role of allogeneic stem cell transplantation in multiple myeloma. Thomson KJ; Peggs KS Expert Rev Anticancer Ther; 2005 Jun; 5(3):455-64. PubMed ID: 16001953 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Harrison SJ; Cook G; Nibbs RJ; Prince HM Expert Rev Anticancer Ther; 2006 Dec; 6(12):1769-85. PubMed ID: 17181491 [TBL] [Abstract][Full Text] [Related]
19. [Interferon therapy in multiple myeloma]. Micksche M Wien Med Wochenschr; 1993; 143(16-17):425-8. PubMed ID: 8273366 [TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma. Ballester OF; Fang T; Raptis A; Ballester G; Wilcox P; Hiemenz J; Tan B Bone Marrow Transplant; 2004 Sep; 34(5):419-23. PubMed ID: 15286696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]